AVGLGAVFLGggkkkggHHHHHHHH

Our HIV Strain V2 Peptide, with the sequence AVGLGAVF, is a crucial tool in the advancement of HIV-1 vaccine development, particularly in the context of eliciting broadly neutralizing antibody responses. This peptide is derived from the fusion peptide (FP) of the HIV-1 Env gp41 subunit, a key target for broad immune recognition in vaccine strategies.

Key Features:

1. Critical in HIV-1 Vaccine Research: The V2 peptide is instrumental in studying the interaction of antibodies with the fusion peptide of HIV-1, a major target for vaccine development.

2. High Relevance to Broad Neutralization: This peptide aids in understanding how antibodies can broadly neutralize diverse HIV-1 strains, a crucial aspect of effective vaccine design.

3. Insight into Antibody Binding Dynamics: The AVGLGAVF sequence is essential for studying the binding behavior of antibodies and their affinity to different FP sequences, providing insights into the energetics of antibody-peptide interactions.

4. Facilitates Vaccine Efficacy Studies: The peptide is vital for research aiming to improve the neutralization breadth of anti-FP vaccines and antibodies against HIV-1.

5. Supports Advanced Vaccine Strategies: Research with this peptide contributes to the development of prime-boost immunization strategies that elicit broad antibody responses against HIV-1.

Applications:

• HIV-1 Vaccine Development: Essential for creating vaccines that elicit broadly neutralizing antibodies against diverse HIV-1 strains.
• Antibody Research: Useful in studying the binding dynamics and energetics of antibodies targeting the HIV-1 FP.
• Neutralization Breadth Analysis: Aids in evaluating and enhancing the breadth of neutralizing responses elicited by HIV-1 vaccines.

Quality Assurance:

Our HIV Strain V2 Peptide is synthesized with precision, ensuring high purity and consistency. Each batch undergoes rigorous quality control and is accompanied by a comprehensive Certificate of Analysis.

AVGLGAVFLGggkkkggHHHHHHHH is a 25-residue synthetic peptide with the sequence Ala-Val-Gly-Leu-Gly-Ala-Val-Phe-Leu-Gly-Gly-Gly-Lys-Lys-Lys-Gly-Gly-His-His-His-His-His-His-His-His. The sequence contains 3 Lys and 0 Arg residues, contributing cationic character. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.